Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 62
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D0552D6AE7FEN
Leaflet:

Download PDF Leaflet

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)
  • The report reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Deep Vein Thrombosis (DVT) therapeutics and enlists all their major and minor projects
  • The report assesses Deep Vein Thrombosis (DVT) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Deep Vein Thrombosis (DVT) Overview
Therapeutics Development
Pipeline Products for Deep Vein Thrombosis (DVT) - Overview
Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis
Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies
Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes
Deep Vein Thrombosis (DVT) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Deep Vein Thrombosis (DVT) - Products under Development by Companies
Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
3SBIO INC.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Generex Biotechnology Corporation
Laboratorios Farmaceuticos Rovi, S.A.
Pharmathen Pharmaceuticals S.A.
Deep Vein Thrombosis (DVT) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARC-15105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-20201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fondaparinux sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-023725 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Deep Vein Thrombosis (DVT) - Dormant Projects
Deep Vein Thrombosis (DVT) - Discontinued Products
Deep Vein Thrombosis (DVT) - Product Development Milestones
Featured News & Press Releases
Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer’s Xarelto Accepted for Presentation at ESC Congress 2016
May 18, 2016: Janssen to Present Data on Rivaroxaban at the 2016 American Society of Clinical Oncology Annual Meeting
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US
Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials
Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy
Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis
Nov 30, 2015: New Data from Bayer’s Portfolio in Thrombosis to be Presented at ASH 2015
Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
May 04, 2015: Bayer’s Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis
Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents
Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc., H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016
Deep Vein Thrombosis (DVT) - Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2016
Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

3SBio Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Generex Biotechnology Corporation
Laboratorios Farmaceuticos Rovi, S.A.
Pharmathen Pharmaceuticals S.A.
Skip to top


Ask Your Question

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: